NCT03014622View on ClinicalTrials.gov

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

December 8, 2016

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Botulinum Toxins, Type A

Intramuscular injection

BIOLOGICAL

Placebos

Intramuscular injection

Trial Locations (15)

10001

New York

10022

New York

27517

Chapel Hill

33146

Coral Gables

33431

Boca Raton

35205

Birmingham

37203

Nashville

48009

Birmingham

80111

Greenwood

90210

Beverly Hills

90404

Santa Monica

92663

Newport Beach

94117

San Francisco

02467

Chestnut Hill

07042

Montclair

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT03014622 - Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter